1. Specific bradycardic agents, a new therapeutic modality for anesthesiology: Hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs;Riley;Anesthesiology,1987
2. Cardiovascular characterization of UL-FS 49, 1, 3, 4, 5-tetrahydro-7, 8-dimethoxy-3-[3-[[2-(3, 4 dimethoxyphenyl) ethyl]methylimino]propyl]-2H-3-benzazepi-n2- on hydrochloride, a new “specific bradycardic agent”;Kobinger;Eur J Pharmacol,1984
3. Cardiovascular actions of UL-FS 49, 1, 3, 4, 5-tetrahydro-7, 8-dimethoxy-3-[3-[[2-(3, 4 dimethoxy-phenyl) ethyl]methylimino]propyl]-2H-3-benzazepin -2- on hydrochloride, a new “specific bradycardic agent”;Lillie;Naunyn Schmiedebergs Arch Pharmacol,1983
4. Investigations into the bradycardic effects of UL-FS 49, 1, 3, 4, 5-tetrahydro-7, 8-dimethoxy-3-[3[[2-(3, 4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride) in isolated guinea pig atria;Lillie;J Cardiovasc Pharmacol,1986
5. The pharmacology of dobutamine;Ruffolo;Am J Med Sci,1987